EGRP's Research Interest Areas
NCI's Epidemiology and Genomics Research Program (EGRP) provides opportunities for investigators to increase understanding of cancer causes and prevention in human populations.
Interest Areas by Branch
- Clinical and Translational Epidemiology Branch
Clinical and translational epidemiology, including factors that influence development of cancer among persons with underlying diseases and conditions; the progression, recurrence, and mortality from cancer; and development of new primary cancers.
- Environmental Epidemiology Branch
Modifiable risk factors to reduce cancer risk in humans, such as diet and nutrition; alcohol; physical activity and energy balance; tobacco; infectious diseases; physical and chemical agents; and medical exposures, including medications and treatments.
- Genomic Epidemiology Branch
Host susceptibility factors that influence personal susceptibility to cancer in humans, such as genetic, epigenetic, immunological, hormonal, and biological pathways; and social, cultural, racial, and ethnic factors.
- Methods and Technologies Branch
Methods and technologies for epidemiologic data collection, study design and analysis, and development and adaptation of laboratory and technical approaches for large studies in human populations.
- Risk Factors Assessment Branch
Development, evaluation, and dissemination of high-quality risk factor metrics, methods, tools, technologies, and resources for use across the cancer research continuum, and the assessment of cancer-related risk factors in the population.
EGRP-Supported Webinars, Seminars, and Workshops
The Epidemiology and Genomics Research Program sponsors webinars, seminars, and workshops to identify barriers and gaps in cancer epidemiology and to advance solutions to study in specific areas.
View Webinars, Seminars, and Workshops
Grantee Research Highlights
Highlights of recent research reported by grantees supported by EGRP, nominated by extramural investigators, and selected by EGRP Program Staff based on scientific merit, innovation, and/or potential public health impact.
Return to Top